Densitometric threshold and vertebral fractures in heart transplant patients

Transplantation

Volumn 92, Issue 1, 2011, Pages 106-111

  Carbonare, Luca Dalle ^a   Zanatta, Mirko ^a   Braga, Vania ^b   Sella, Stefania ^c   Vilei, Maria Teresa ^c   Feltrin, Giuseppe ^c   Gambino, Antonio ^c   Pepe, Ilenia ^d   Rossini, Maurizio ^b   Adami, Silvano ^b   Giannini, Sandro ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Densitometry; Heart transplantation; Immunosuppressant treatment; Vertebral fracture; Vitamin D

Indexed keywords

CYCLOSPORIN A; GLUCOCORTICOID;

ADULT; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE METABOLISM; BONE SCINTISCANNING; CARDIAC GRAFT REJECTION; CROSS-SECTIONAL STUDY; FEMALE; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; BONE DENSITY; BONE DISEASES, METABOLIC; CROSS-SECTIONAL STUDIES; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS; SPINAL FRACTURES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 79959653212     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31821cdeef     Document Type: Article

References (38)

1. Van Cleemput J, Daenen W, Nijs J, et al. Timing and quantification of bone loss in cardiac transplant recipients. Transpl Int 1995; 8: 196.
2. Sambrook PN, Kelly PJ, Fontana D, et al. Mechanism of rapid bone loss following cardiac transplantation. Osteoporos Int 1994; 4: 273.
3. Cohen A, Ebeling P, Sprague S, et al. Transplantation osteoporosis. In: Favus MJ, ed. Primer on the metabolic disease and disorders of mineral metabolism [ed. 5]. WA, D.C., American Society for Bone Miner Research 2003, pp 370.
4. Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104: 1363.
5. Shane E, Rivas M, McMahon DJ, et al. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab 1997; 82: 1947.
6. Epstein S. Post transplantation bone disease: The role of immunosuppressive agents and the skeleton. J Bone Miner Res 1996; 11: 1.
7. Lukert B, Kream BE. Clinical and basic aspect of glucocorticoid action in bone. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. New York, Academic Press 1996, pp 533.
8. Schlosberg M, Movsowitz C, Epstein S, et al. The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 1989; 124: 2179.
9. Seethalakshmi L, Flores C, Malhotra RK, et al. The mechanism of cyclosporine's action in the inhibition of testosterone biosynthesis by rat Leydig cells in vitro. Endocrinology 1992; 53: 190.
10. Sikka CS, Bhasin S, Coy DC, et al. Effects of cyclosporine on the hypothalamic-pituitary-gonadal axis in the male rat: Mechanism of action. Endocrinology 1988; 123: 1069.
11. Buchinsky FJ, Ma YF, Mann G, et al. T lymphocytes play a critical role in the development of cyclosporine A-induced osteopenia. Endocrinology 1996; 137: 2278.
12. Berguer DG, Krieg MA, Thiébaud D, et al. Osteoporosis in heart transplant recipients: A longitudinal study. Trasplant Proc 1994; 26: 2649.
13. Leidig-Brucker G, Hosch S, Dodidou P, et al. Frequency and prediction of osteoporotic fracture after cardiac or liver transplantation: A follow up study. Lancet 2001; 357: 342.
14. Muchmore JS, Cooper DK, Ye Y, et al. Loss of vertebral bone density in heart transplant patients. Transplant Proc 1991; 23: 1184.
15. Meys E, Terreaux-Duvert F, Beaume-Six T, et al. Bone loss after cardiac transplantation: Effect of calcium, calcidiol and monofluorophosphate. Osteoporos Int 1993; 3: 322.
16. Lee AH, Mull RL, Keenan GF, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 1994; 96: 35.
17. Shane E, Rivas M, Staron RB, et al. Fracture after cardiac transplantation: A prospective longitudinal study. J Clin Endocrinol Metab 1996; 81: 1740.
18. Shane E, Rivas M, Silveberg SJ, et al. Osteoporosis after cardiac transplantation. Am J Med 1993; 94: 257.
19. Kerschan-Schindl K, Ruzicka M, Mahr S, et al. Unexpected low incidence of vertebral fractures in heart transplant recipients: Analysis of bone turnover. Transpl Int 2008; 21: 255.
20. Höfle G, Saely CH, Tautermann G, et al. Relationship between various measures of bone mineral density and vertebral fractures in cardiac transplant recipients. Swiss Med Wkly 2004; 134: 215.
21. Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Artrhitis Rheum 2003; 48: 3224.
22. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twentyseventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 2010; 29: 1104.
23. Adams JS, Hewison MJ. Update in vitamin D. Clin Endocrinol Metab 2010; 95: 471.
24. Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009; 20: 239.
25. Robbins JA, Schott AM, Garnero P, et al. Risk factors for hip fracture in women with high BMD: EPIDOS study. Osteoporos Int 2005; 16: 149.
26. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993.
27. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385.
28. Souberbielle JC, Body JJ, Lappe JM, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev 2010; 9: 709.
29. Bischoff-Ferrari H. Vitamin D: What is an adequate vitamin D level and how much supplementation is necessary? Best Pract Res Clin Rheumatol 2009; 23: 789.
30. Ebeling PR. Approach to the patient with transplantation-related bone loss. J Clin Endocrinol Metab 2009; 94: 1483.
31. Pagani F, Francucci CM, Moro L. Markers of bone turnover: Biochemical and clinical perspectives. J Endocrinol Invest 2005; 28: 8.
32. Melton LJ III, Khosla S, Atkinson EJ, et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997; 12: 1083.
33. Crawford BA, Kam C, Pavlovic J, et al. Zoledronic acid prevents bone loss after liver transplantation: A randomized, double-blind, placebo controlled trial. Ann Intern Med 2006; 144: 239.
34. Giannini S, D'Angelo A, Carraro G, et al. Alendronate prevents further bone loss in renal transplant recipients. Bone Miner Res 2001; 16: 2111.
35. Movsowitz C, Schlosberg M, Epstein S, et al. Combined treatment with cyclosporin A and cortisone acetate minimizes the adverse bone effects of either agent alone. J Orthop Res 1990; 8: 635.
36. Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137.
37. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18: 1051.
38. Genant HK, Jergas M, Palermo L, et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1996; 11: 984.